Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: Updated result of a Phase 1b/2 study Meeting Abstract
| Authors: | Matasar, M.; Herrera, A. F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T. M.; Kim, W. S.; Bosch, F.; Radford, J.; Flowers, C. R.; Bu, L.; Hong, W.; Sehn, L. H. |
| Abstract Title: | Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: Updated result of a Phase 1b/2 study |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 271 |
| End Page: | 272 |
| Language: | English |
| ACCESSION: | 123459667 |
| DOI: | 10.1002/hon.2438_144 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 284 -- Accession Number: 123459667 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
